AstraZeneca’s (AZN) products under its other products category include Nexium, Synagis, and Movantik. Total sales from this category declined by 31.0% to $747.0 million in the second quarter. During the second quarter, Nexium’s sales fell by 28.0% to $442.0 million, Synagis’s sales declined by 63.0% to $26.0 million, and Movantik’s sales declined by 25.0% to $24.0 million.
The share of other product sales in AstraZeneca’s total revenues decreased from 21.0% in the first half of 2017 to 17.0% in the first half. The decrease in Nexium’s sales was attributable to weaker performance in the United States and price cuts in Japan in April.
AstraZeneca’s geographic segments include emerging markets, the United States, Europe, and the rest of the world. The company’s total emerging market sales increased 12.0% to $1.66 billion in the second quarter.
AstraZeneca’s sales in China surged by 26.0% to $868.0 million in the second quarter. Its sales in the emerging markets excluding China remained flat at $791.0 million in the second quarter. The increase in product sales in China was attributable to the inclusion of Onglyza, Iressa, Brilinta, Faslodex, and Seroquel XR in the NRDL in China in 2017.
AstraZeneca’s US sales increased by 6.0% to $1.61 billion while its Europe sales decreased 17.0% to $1.03 billion in the second quarter. The increase in its US sales was attributable to the strong performance of Lynparza, Tagrisso, Imfinzi, and Faserna.
The company’s product sales in the rest of the world region declined by 15.0% to $723.0 million in the second quarter.
We’ll analyze AstraZeneca’s valuation metrics in the final part of this series.